Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsCurrent Deferred RevenueGoodwill & IntangiblesIntangiblesInventoryLiabilities and Shareholders EquityNon-Current AssetsNon-Current DebtNotes PayablesOther Accumulated ExpensesPayablesPreferred SharesPrepaid AssetsProperty, Plant & Equipment (Net)Property, Plant & Equipment (Net)ReceivablesReceivables - NetRetained EarningsShareholder's EquityShares OutstandingShort term DebtTotal Current LiabilitiesTotal DebtTotal Liabilities
Cash Flow Statement
Growth Metrics
Income Statement
Others
Ratios

Bioregenx (BRGX) Retained Earnings (2021 - 2025)

Bioregenx has reported Retained Earnings over the past 5 years, most recently at -$37.1 million for Q4 2025.

  • For Q4 2025, Retained Earnings fell 4.34% year-over-year to -$37.1 million; the TTM value through Dec 2025 reached -$37.1 million, down 4.34%, while the annual FY2025 figure was -$37.1 million, 4.34% down from the prior year.
  • Retained Earnings for Q4 2025 was -$37.1 million at Bioregenx, down from -$36.1 million in the prior quarter.
  • Over five years, Retained Earnings peaked at $99.0 in Q1 2024 and troughed at -$37.1 million in Q4 2025.
  • A 5-year average of -$12.7 million and a median of -$3.4 million in 2023 define the central range for Retained Earnings.
  • On a YoY basis, Retained Earnings climbed as much as 100.0% in 2024 and fell as far as 3776120.28% in 2024.
  • Year by year, Retained Earnings stood at -$2.8 million in 2021, then dropped by 4.19% to -$2.9 million in 2022, then surged by 99.97% to -$942.0 in 2023, then tumbled by 3776120.28% to -$35.6 million in 2024, then fell by 4.34% to -$37.1 million in 2025.
  • Business Quant data shows Retained Earnings for BRGX at -$37.1 million in Q4 2025, -$36.1 million in Q3 2025, and -$36.0 million in Q2 2025.